Abstract
Summary
The global Huntington's Disease Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Huntington's Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Huntington's Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Huntington's Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Huntington's Disease Treatment players cover AInylam Pharmaceuticals Inc, AmpliPhi Biosciences Corp, Ceregene Inc, Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd, Cortex Pharmaceuticals Inc, Vertex Pharmaceuticals Incorporated and Auspex Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Huntington's disease is an infrequent inherited neurodegenerative disease that affects various generations. The impact of this disease is high when the age is between 30 and 50, hampering their ability to work, care for families, and eventually complete daily tasks. The generality difers by more than ten-fold between geographical areas, which can be associated with differences in case ascertainments and diagnostic criteria. As a result, the generality of enlarged replications in the general population may be larger than expected. The Asian population has continuously had a lower generality, while Europe, North America, and Australia have a higher generality.
LPI (LP Information)' newest research report, the “Huntington's Disease Treatment Industry Forecast” looks at past sales and reviews total world Huntington's Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Huntington's Disease Treatment sales for 2023 through 2029. With Huntington's Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Huntington's Disease Treatment industry.
This Insight Report provides a comprehensive analysis of the global Huntington's Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Huntington's Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Huntington's Disease Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Huntington's Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Huntington's Disease Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Huntington's Disease Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tetrabenazine
Selective Serotonin Reuptake Inhibitor
Chlorpromazine
Haloperidol
Risperidone
Olanzapine
Clozapine
Other
Segmentation by application
Hospital
Specialty Clinic
other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AInylam Pharmaceuticals Inc
AmpliPhi Biosciences Corp
Ceregene Inc
Lundbeck
Prana Biotechnology Limited
Teva Pharmaceutical Industries Ltd
Cortex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated
Auspex Pharmaceuticals
SOM Biotech
GlaxoSmithKline
Siena Biotech
Raptor Pharmaceutical
Pfizer
Palobiofarma
Omeros
Ipsen
Valeant Pharmaceuticals International Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Huntington's Disease Treatment market?
What factors are driving Huntington's Disease Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Huntington's Disease Treatment market opportunities vary by end market size?
How does Huntington's Disease Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
United States market for Huntington's Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Huntington's Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Huntington's Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Huntington's Disease Treatment players cover AInylam Pharmaceuticals Inc, AmpliPhi Biosciences Corp, Ceregene Inc, Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd, Cortex Pharmaceuticals Inc, Vertex Pharmaceuticals Incorporated and Auspex Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Huntington's disease is an infrequent inherited neurodegenerative disease that affects various generations. The impact of this disease is high when the age is between 30 and 50, hampering their ability to work, care for families, and eventually complete daily tasks. The generality difers by more than ten-fold between geographical areas, which can be associated with differences in case ascertainments and diagnostic criteria. As a result, the generality of enlarged replications in the general population may be larger than expected. The Asian population has continuously had a lower generality, while Europe, North America, and Australia have a higher generality.
LPI (LP Information)' newest research report, the “Huntington's Disease Treatment Industry Forecast” looks at past sales and reviews total world Huntington's Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Huntington's Disease Treatment sales for 2023 through 2029. With Huntington's Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Huntington's Disease Treatment industry.
This Insight Report provides a comprehensive analysis of the global Huntington's Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Huntington's Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Huntington's Disease Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Huntington's Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Huntington's Disease Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Huntington's Disease Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tetrabenazine
Selective Serotonin Reuptake Inhibitor
Chlorpromazine
Haloperidol
Risperidone
Olanzapine
Clozapine
Other
Segmentation by application
Hospital
Specialty Clinic
other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AInylam Pharmaceuticals Inc
AmpliPhi Biosciences Corp
Ceregene Inc
Lundbeck
Prana Biotechnology Limited
Teva Pharmaceutical Industries Ltd
Cortex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated
Auspex Pharmaceuticals
SOM Biotech
GlaxoSmithKline
Siena Biotech
Raptor Pharmaceutical
Pfizer
Palobiofarma
Omeros
Ipsen
Valeant Pharmaceuticals International Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Huntington's Disease Treatment market?
What factors are driving Huntington's Disease Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Huntington's Disease Treatment market opportunities vary by end market size?
How does Huntington's Disease Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Huntington's Disease Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Huntington's Disease Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Huntington's Disease Treatment by Country/Region, 2018, 2022 & 2029
2.2 Huntington's Disease Treatment Segment by Type
2.2.1 Tetrabenazine
2.2.2 Selective Serotonin Reuptake Inhibitor
2.2.3 Chlorpromazine
2.2.4 Haloperidol
2.2.5 Risperidone
2.2.6 Olanzapine
2.2.7 Clozapine
2.2.8 Other
2.3 Huntington's Disease Treatment Sales by Type
2.3.1 Global Huntington's Disease Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Huntington's Disease Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Huntington's Disease Treatment Sale Price by Type (2018-2023)
2.4 Huntington's Disease Treatment Segment by Application
2.4.1 Hospital
2.4.2 Specialty Clinic
2.4.3 other
2.5 Huntington's Disease Treatment Sales by Application
2.5.1 Global Huntington's Disease Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Huntington's Disease Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Huntington's Disease Treatment Sale Price by Application (2018-2023)
3 Global Huntington's Disease Treatment by Company
3.1 Global Huntington's Disease Treatment Breakdown Data by Company
3.1.1 Global Huntington's Disease Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Huntington's Disease Treatment Sales Market Share by Company (2018-2023)
3.2 Global Huntington's Disease Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Huntington's Disease Treatment Revenue by Company (2018-2023)
3.2.2 Global Huntington's Disease Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Huntington's Disease Treatment Sale Price by Company
3.4 Key Manufacturers Huntington's Disease Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Huntington's Disease Treatment Product Location Distribution
3.4.2 Players Huntington's Disease Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Huntington's Disease Treatment by Geographic Region
4.1 World Historic Huntington's Disease Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Huntington's Disease Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Huntington's Disease Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Huntington's Disease Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Huntington's Disease Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Huntington's Disease Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Huntington's Disease Treatment Sales Growth
4.4 APAC Huntington's Disease Treatment Sales Growth
4.5 Europe Huntington's Disease Treatment Sales Growth
4.6 Middle East & Africa Huntington's Disease Treatment Sales Growth
5 Americas
5.1 Americas Huntington's Disease Treatment Sales by Country
5.1.1 Americas Huntington's Disease Treatment Sales by Country (2018-2023)
5.1.2 Americas Huntington's Disease Treatment Revenue by Country (2018-2023)
5.2 Americas Huntington's Disease Treatment Sales by Type
5.3 Americas Huntington's Disease Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Huntington's Disease Treatment Sales by Region
6.1.1 APAC Huntington's Disease Treatment Sales by Region (2018-2023)
6.1.2 APAC Huntington's Disease Treatment Revenue by Region (2018-2023)
6.2 APAC Huntington's Disease Treatment Sales by Type
6.3 APAC Huntington's Disease Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Huntington's Disease Treatment by Country
7.1.1 Europe Huntington's Disease Treatment Sales by Country (2018-2023)
7.1.2 Europe Huntington's Disease Treatment Revenue by Country (2018-2023)
7.2 Europe Huntington's Disease Treatment Sales by Type
7.3 Europe Huntington's Disease Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Huntington's Disease Treatment by Country
8.1.1 Middle East & Africa Huntington's Disease Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Huntington's Disease Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Huntington's Disease Treatment Sales by Type
8.3 Middle East & Africa Huntington's Disease Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Huntington's Disease Treatment
10.3 Manufacturing Process Analysis of Huntington's Disease Treatment
10.4 Industry Chain Structure of Huntington's Disease Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Huntington's Disease Treatment Distributors
11.3 Huntington's Disease Treatment Customer
12 World Forecast Review for Huntington's Disease Treatment by Geographic Region
12.1 Global Huntington's Disease Treatment Market Size Forecast by Region
12.1.1 Global Huntington's Disease Treatment Forecast by Region (2024-2029)
12.1.2 Global Huntington's Disease Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Huntington's Disease Treatment Forecast by Type
12.7 Global Huntington's Disease Treatment Forecast by Application
13 Key Players Analysis
13.1 AInylam Pharmaceuticals Inc
13.1.1 AInylam Pharmaceuticals Inc Company Information
13.1.2 AInylam Pharmaceuticals Inc Huntington's Disease Treatment Product Portfolios and Specifications
13.1.3 AInylam Pharmaceuticals Inc Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AInylam Pharmaceuticals Inc Main Business Overview
13.1.5 AInylam Pharmaceuticals Inc Latest Developments
13.2 AmpliPhi Biosciences Corp
13.2.1 AmpliPhi Biosciences Corp Company Information
13.2.2 AmpliPhi Biosciences Corp Huntington's Disease Treatment Product Portfolios and Specifications
13.2.3 AmpliPhi Biosciences Corp Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AmpliPhi Biosciences Corp Main Business Overview
13.2.5 AmpliPhi Biosciences Corp Latest Developments
13.3 Ceregene Inc
13.3.1 Ceregene Inc Company Information
13.3.2 Ceregene Inc Huntington's Disease Treatment Product Portfolios and Specifications
13.3.3 Ceregene Inc Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Ceregene Inc Main Business Overview
13.3.5 Ceregene Inc Latest Developments
13.4 Lundbeck
13.4.1 Lundbeck Company Information
13.4.2 Lundbeck Huntington's Disease Treatment Product Portfolios and Specifications
13.4.3 Lundbeck Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Lundbeck Main Business Overview
13.4.5 Lundbeck Latest Developments
13.5 Prana Biotechnology Limited
13.5.1 Prana Biotechnology Limited Company Information
13.5.2 Prana Biotechnology Limited Huntington's Disease Treatment Product Portfolios and Specifications
13.5.3 Prana Biotechnology Limited Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Prana Biotechnology Limited Main Business Overview
13.5.5 Prana Biotechnology Limited Latest Developments
13.6 Teva Pharmaceutical Industries Ltd
13.6.1 Teva Pharmaceutical Industries Ltd Company Information
13.6.2 Teva Pharmaceutical Industries Ltd Huntington's Disease Treatment Product Portfolios and Specifications
13.6.3 Teva Pharmaceutical Industries Ltd Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.6.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.7 Cortex Pharmaceuticals Inc
13.7.1 Cortex Pharmaceuticals Inc Company Information
13.7.2 Cortex Pharmaceuticals Inc Huntington's Disease Treatment Product Portfolios and Specifications
13.7.3 Cortex Pharmaceuticals Inc Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Cortex Pharmaceuticals Inc Main Business Overview
13.7.5 Cortex Pharmaceuticals Inc Latest Developments
13.8 Vertex Pharmaceuticals Incorporated
13.8.1 Vertex Pharmaceuticals Incorporated Company Information
13.8.2 Vertex Pharmaceuticals Incorporated Huntington's Disease Treatment Product Portfolios and Specifications
13.8.3 Vertex Pharmaceuticals Incorporated Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Vertex Pharmaceuticals Incorporated Main Business Overview
13.8.5 Vertex Pharmaceuticals Incorporated Latest Developments
13.9 Auspex Pharmaceuticals
13.9.1 Auspex Pharmaceuticals Company Information
13.9.2 Auspex Pharmaceuticals Huntington's Disease Treatment Product Portfolios and Specifications
13.9.3 Auspex Pharmaceuticals Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Auspex Pharmaceuticals Main Business Overview
13.9.5 Auspex Pharmaceuticals Latest Developments
13.10 SOM Biotech
13.10.1 SOM Biotech Company Information
13.10.2 SOM Biotech Huntington's Disease Treatment Product Portfolios and Specifications
13.10.3 SOM Biotech Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 SOM Biotech Main Business Overview
13.10.5 SOM Biotech Latest Developments
13.11 GlaxoSmithKline
13.11.1 GlaxoSmithKline Company Information
13.11.2 GlaxoSmithKline Huntington's Disease Treatment Product Portfolios and Specifications
13.11.3 GlaxoSmithKline Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 GlaxoSmithKline Main Business Overview
13.11.5 GlaxoSmithKline Latest Developments
13.12 Siena Biotech
13.12.1 Siena Biotech Company Information
13.12.2 Siena Biotech Huntington's Disease Treatment Product Portfolios and Specifications
13.12.3 Siena Biotech Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Siena Biotech Main Business Overview
13.12.5 Siena Biotech Latest Developments
13.13 Raptor Pharmaceutical
13.13.1 Raptor Pharmaceutical Company Information
13.13.2 Raptor Pharmaceutical Huntington's Disease Treatment Product Portfolios and Specifications
13.13.3 Raptor Pharmaceutical Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Raptor Pharmaceutical Main Business Overview
13.13.5 Raptor Pharmaceutical Latest Developments
13.14 Pfizer
13.14.1 Pfizer Company Information
13.14.2 Pfizer Huntington's Disease Treatment Product Portfolios and Specifications
13.14.3 Pfizer Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Pfizer Main Business Overview
13.14.5 Pfizer Latest Developments
13.15 Palobiofarma
13.15.1 Palobiofarma Company Information
13.15.2 Palobiofarma Huntington's Disease Treatment Product Portfolios and Specifications
13.15.3 Palobiofarma Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Palobiofarma Main Business Overview
13.15.5 Palobiofarma Latest Developments
13.16 Omeros
13.16.1 Omeros Company Information
13.16.2 Omeros Huntington's Disease Treatment Product Portfolios and Specifications
13.16.3 Omeros Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Omeros Main Business Overview
13.16.5 Omeros Latest Developments
13.17 Ipsen
13.17.1 Ipsen Company Information
13.17.2 Ipsen Huntington's Disease Treatment Product Portfolios and Specifications
13.17.3 Ipsen Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Ipsen Main Business Overview
13.17.5 Ipsen Latest Developments
13.18 Valeant Pharmaceuticals International Inc
13.18.1 Valeant Pharmaceuticals International Inc Company Information
13.18.2 Valeant Pharmaceuticals International Inc Huntington's Disease Treatment Product Portfolios and Specifications
13.18.3 Valeant Pharmaceuticals International Inc Huntington's Disease Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Valeant Pharmaceuticals International Inc Main Business Overview
13.18.5 Valeant Pharmaceuticals International Inc Latest Developments
14 Research Findings and Conclusion